Frankfurt - Delayed Quote EUR

Regulus Therapeutics Inc. (7RG0.F)

6.85

-0.15

(-2.14%)

At close: May 30 at 8:01:50 AM GMT+2

Regulus: Q1 Earnings Snapshot

SAN DIEGO (AP) — Regulus Therapeutics Inc. RGLS) on Thursday reported a loss of $9.6 million in its first quarter. The San Diego-based company said it had a loss of 15 cents per share.

Associated Press Finance 23 days ago

RGLS
Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.

PR Newswire 23 days ago

RGLS
Novartis to buy Regulus Therapeutics for as much as $1.7 billion

Novartis AG has agreed to buy U.S. biotech firm Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.

LA Times 30 days ago

NVS

RGLS
Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 6,307% surge in interest CG Oncology (CGON), 3,377% surge in interest Chemomab Therapeutics (CMMB), 3,029% surge in interest BioCardia (BCDA), 1,244% surge in interest Senti Biosciences (SNTI), 1,175% surge in interest Tevogen Bio Holdings (TVGN), 332% surge in interest Regulus Therapeutics (RGLS), 223% surge in interest Spr

TipRanks last month

NVS

NVSEF

RGLS
Novartis to strengthen renal disease portfolio with Regulus

Total consideration for the acquisition, including the CVR, could reach $1.7bn.

Pharmaceutical Technology last month

NVS

RGLS
Novartis to acquire Regulus in deal for kidney disease drug

The pharma will pay $800 million for the biotech, which was launched nearly two decades ago by Alnylam and Ionis to advance microRNA technology.

BioPharma Dive last month

NVS

RGLS
Novartis to Acquire Regulus in $1.7 Billion Deal

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.

The Wall Street Journal last month

NVS

NVSEF

RGLS
Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal

(Reuters) -Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental drug to treat a life-threatening kidney disease. Under the deal terms, Novartis will pay $7 per share in cash upfront, or about $800 million, and another $7 per share to Regulus shareholders if the lead drug candidate, farabursen, gets regulatory approval, the California-based biotech said on Wednesday. The deal, expected to bolster Novartis' lineup of kidney disease drugs in development, will also give the company access to Regulus' proprietary platform to develop treatments targeting a type of genetic material called microRNAs.

Reuters last month

NVS

RGLS
Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will acquire Regulus for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. The upfront cash portion of th

PR Newswire last month

RGLS
Promising Penny Stocks To Consider In April 2025

Over the last 7 days, the United States market has risen by 7.1%, with a 12-month increase of 7.7% and earnings forecasted to grow by 14% annually. In light of these conditions, investors may find value in exploring stocks that combine strong financial health with growth potential, even within the niche category of penny stocks. Although considered somewhat outdated, penny stocks still represent an intriguing segment for those interested in smaller or newer companies that might offer...

Simply Wall St. last month

TRVG

RGLS

SOPH
Should You Buy Regulus (RGLS) After Golden Cross?

Is it a good or bad thing when a stock experiences a golden cross technical event?

Zacks last month

RGLS
Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?

We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]

Insider Monkey last month

RGLS

^RUT
Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, CEO, will participate in a presentation at the 2025 Oppenheimer Innovation on the Island Biotech Summit on Wednesday, April 9th at 11:32 a.m. ET.

PR Newswire last month

RGLS
Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks

Amid recent market fluctuations and economic uncertainties, investors are seeking opportunities that can weather the storm. Penny stocks, a term that might seem outdated, continue to hold potential for those willing to explore beyond the mainstream. These stocks often represent smaller or newer companies and can offer growth prospects at lower price points when backed by strong financials. In this article, we explore three promising penny stocks that stand out as potential hidden gems in...

Simply Wall St. 2 months ago

RGLS

DIBS
Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index up 0.3% and

PREMIUM
MT Newswires 2 months ago

PFE

WBA

RGLS
Top Midday Gainers

23andMe (ME) shares rose sharply amid heavy trading Thursday after a court authorized the company to

PREMIUM
MT Newswires 2 months ago

RGLS

ME
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen for the treatment of ADPKD.

PR Newswire 2 months ago

RGLS
Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now

We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Regulus Therapeutics Inc. (NASDAQ:RGLS) stands against other best short-term stocks with a buying opportunity for investors. Thrilling highs, daunting lows, and the energized chase after the next big opportunity […]

Insider Monkey 2 months ago

RGLS
Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 2 months ago

RGLS
Regulus: Q4 Earnings Snapshot

SAN DIEGO (AP) — Regulus Therapeutics Inc. RGLS) on Thursday reported a loss of $12.8 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 20 cents.

Associated Press Finance 2 months ago

RGLS

Performance Overview

Return	7RG0.F	S&P 500 (^GSPC)
YTD	+375.69%	+0.51%
1-Year	+258.64%	+12.92%
3-Year	+128.33%	+42.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Regulus Therapeutics Inc. (7RG0.F)

Regulus: Q1 Earnings Snapshot

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

Novartis to buy Regulus Therapeutics for as much as $1.7 billion

Biotech Alert: Searches spiking for these stocks today

Novartis to strengthen renal disease portfolio with Regulus

Novartis to acquire Regulus in deal for kidney disease drug

Novartis to Acquire Regulus in $1.7 Billion Deal

Novartis to buy kidney disease drug maker Regulus in up to $1.7 billion deal

Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG

Promising Penny Stocks To Consider In April 2025

Should You Buy Regulus (RGLS) After Golden Cross?

Is Regulus Therapeutics Inc. (RGLS) the Best Rising Penny Stock to Buy According to Analysts?

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

Regulus Therapeutics Leads The Charge Among 3 Promising Penny Stocks

Sector Update: Health Care Stocks Advance Late Afternoon

Top Midday Gainers

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics (RGLS): One of the Best Short-Term Stocks to Buy Right Now

Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth?

Regulus: Q4 Earnings Snapshot

Performance Overview